41Indexed trials
Market Rank #47 · Evidence Tier A
Colombia
Neuroscience Intelligence
Colombia neuroscience intelligence: 41 indexed trials, 6 institutions, research score 23.89.
11Recruiting
6Research institutions
23.9Research score
Evidence profile
23Sponsors
14Disease areas
0Institution works
0Institution citations
Model signals
Opportunity 24 · ML priority 24 · Confidence 85 · Evidence 23.9
These are comparative evidence signals. They do not represent a guarantee of market size or commercial outcome.
Leading disease areas
parkinsons10trials
schizophrenia3trials
stroke3trials
alzheimers3trials
depression3trials
pain_neuropathy3trials
other_neurology3trials
epilepsy2trials
autism2trials
traumatic_brain_injury1trials
Leading indexed sponsors
Merck Sharp & Dohme LLC10trials
Washington University School of Medicine3trials
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.3trials
Forest Laboratories2trials
Hoffmann-La Roche2trials
AbbVie2trials
Pfizer2trials
Sumitomo Pharma America, Inc.2trials
Fundación Cardiovascular de Colombia1trials
AstraZeneca1trials